GSK3B and hepatocellular carcinoma: Our data allows us to further understand the biological processes underlying NDRG1-associated tumor aggressiveness, and also suggests new avenues for developing therapeutic approaches for HCC, such as through the disruption of NDRG1 interaction with GSK-3β and/or Nur77.